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Abstract: E-cadherin (CDH1 gene) germline mutations are associated with the development of
diffuse gastric cancer in the context of the so-called hereditary diffuse gastric syndrome, and with an
inherited predisposition of lobular breast carcinoma. In 2019, the international gastric cancer linkage
Cancers 2020, 12, 1598; doi:10.3390/cancers12061598 www.mdpi.com/journal/cancers
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consortium revised the clinical criteria and established guidelines for the genetic screening of CDH1
germline syndromes. Nevertheless, the introduction of multigene panel testing in clinical practice
has led to an increased identification of E-cadherin mutations in individuals without a positive family
history of gastric or breast cancers. This observation motivated us to review and present a novel
multidisciplinary clinical approach (nutritional, surgical, and image screening) for single subjects
who present germline CDH1 mutations but do not fulfil the classic clinical criteria, namely those
identified as—(1) incidental finding and (2) individuals with lobular breast cancer without family
history of gastric cancer (GC).
Keywords: gastric cancer; breast cancer; E-cadherin; CDH1 gene; germline mutations; hereditary
syndrome; prophylactic surgery
1. Introduction
Since the early discovery of CDH1 germline mutations in Maori kindred [1], clinical interest in
this cancer predisposition syndrome has progressively increased. Families affected by CDH1 germline
mutations show a strong aggregation for diffuse gastric cancer (DGC) and lobular breast cancer
(LBC) [2]. In 1999, the International Gastric Cancer Linkage Consortium (IGCLC), defined specific
clinical criteria to select individuals for CDH1 genetic screening and introduced the definition of a new
syndrome, the so-called Hereditary Diffuse Gastric Cancer (HDGC) [3]. The detection rate of CDH1
mutations using the first guidelines published by the IGCLC in 1999, was approximately 40% [4].
However, since CDH1 germline mutations were also identified in individuals who did not meet these
criteria (such as those with sporadic early onset DGC and those with LBC without a family history of
DGC), those criteria for CDH1 genetic testing were subsequently revised [5–7]. In individuals who
meet the IGCLC 2010 criteria [6], the cumulative incidence of GC at age 80 years is 70% (95% CI, 59–80%)
for males and 56% (95% CI, 44–69%) for females. The risk of breast cancer (BC) for females in the same
study was 42% (95% CI, 23–68%) [8]. Roberts and colleagues recently reported that in individuals with
CDH1 pathogenic variants identified by the MultiGene Panel Testing (MGPT), who did not meet the
established clinical testing criteria, the cumulative incidence of GC at age 80 years was significantly
lower: 42% (95% CI, 30–56%) for men and 33% (95% CI, 21–43%) for women [9]. The identification
of unexpected CDH1 germline mutations in the absence of specific clinical criteria suggests that the
HDGC syndrome might be a more complex syndrome than the one originally defined. Additionally,
the low frequency of pathogenic variants in countries with high-incidence of GC has opened new
discussions about the clinical management of this syndrome. In this multidisciplinary clinical review,
the following major topics will be reviewed: (a) GC epidemiology and the strategies to reduce its
risk; (b) CDH1 genetic testing in HLBC; (d) clinical and laboratory management of CDH1 missense
mutations; and (e) prophylactic surgery, including gastrectomy and mastectomy.
2. Hereditary Diffuse Gastric Cancer
In Figure 1, we purposed a flow-chart for the clinical management of the HDGC syndrome.
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Figure 1. The flow-chart describes the clinical management of hereditary diffuse gastric cancer 
syndrome [* If refuse PTG (prophylactic total gastrectomy) consider gastric endoscopic surveillance 
with Cambridge protocol]. 
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Despite a substantial fall in mortality over the last century, GC remains the third cause of cancer 
death worldwide [10,11]. Nonetheless, until recently it received little attention both in terms of 
prevention and research efforts. In 2012, in order to meet this need, a global consortium, the «Stomach 
cancer Pooling» (StoP) project was launched [12]. The StoP project is a consortium of epidemiological 
studies including case-control studies, and nested case-controls within cohort studies. The main aim 
of the StoP project is to examine the role of several lifestyle and genetic determinants in the etiology 
of GC, through pooled analyses of individual-level data. Helicobacter pylori (Hp) is known to be the 
major risk factor for non-cardia stomach cancer. An independent effect of sex on the prevalence of 
Hp infection has been identified—compared to women, men have a significantly higher risk [odds 
ratio (OR), 1.33, 95% confidence interval (CI), 1.04–1.70]. Cigarette smoking and heavy alcohol 
consumption are other well-known risk factors for GC, with a 40% excess risk in smokers versus non-
smokers [13] and a 50% increased risk for heavy drinkers compared to never drinkers [14]. As for 
many other cancers, low socioeconomic status has also been identified as a risk factor for GC; in the 
latest StoP analysis, the pooled OR for the highest compared to the lowest level of education was 0.60 
(95% CI, 0.44–0.84) [15]. With reference to dietary factors, data from the StoP project confirmed that 
meat consumption is a risk factor [16], whereas fruit intake is protective [17]. The interaction of all 
these environmental factors and HDGC, remains unquantified nowadays. 
2.2. Pathology of HDGC 
The morphology of HDGC encompasses a spectrum of histopathological lesions that should be 
searched for and characterized in biopsy specimens from CDH1 carriers. The specific lesions in 
HDGC are tiny foci of typical signet ring cells (SRC), usually confined to the superficial lamina 
propria, without infiltration beneath the muscularis mucosae. Neoplastic cells are usually small in 
the deep level at the neck gland zone and enlarge towards the surface. Furthermore, two pre-invasive 
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2.1. Environmental Factors and GC
Despite a substantial fall in mortality over the last century, GC remains the third cause of cancer
death worldwide [10,11]. Nonetheless, until recently it received little attention both in terms of
prevention and research efforts. In 2012, in order to meet this need, a global consortium, the «Stomach
cancer Pooling» (StoP) project was launched [12]. The StoP project is a consortium of epidemiological
studies including case-control studies, and nested case-controls within cohort studies. The main aim of
the StoP project is to examine the role of several lifestyle and genetic determinants in the etiology of
GC, through pooled analyses of individual-level data. Helicobacter pylori (Hp) is known to be the
major risk factor for non-cardia stomach cancer. An independent effect of sex on the prevalence of Hp
infection has been identified—compared to women, men have a significantly higher risk [odds ratio
(OR), 1.33, 95% confidence interval (CI), 1.04–1.70]. Cigarette smoking and heavy alcohol consumption
are other well-known risk factors for GC, with a 40% excess risk in smokers versus non-smokers [13]
and a 50% increased risk for heavy drinkers compared to never drinkers [14]. As for many other
cancers, low socioeconomic status has also been identified as a risk factor for GC; in the latest StoP
analysis, the pooled OR for the highest compared to the lowest level of education was 0.60 (95% CI,
0.44–0.84) [15]. With reference to dietary factors, data from the StoP project confirmed that meat
consumption is a risk factor [16], whereas fruit intake is protective [17]. The interaction of all these
environmental factors and HDGC, remains unquantified nowadays.
2.2. Pathology of HDGC
The morphology of HDGC encompasses a spectrum of histopathological lesions that should
be searched for and characterized in biopsy specimens from CDH1 carriers. The specific lesions in
HDGC are tiny foci of typical signet ring cells (SRC), usually confined to the superficial lamina propria,
without infiltration beneath the muscularis mucosae. Neoplastic cells are usually small in the deep
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level at the neck gland zone and enlarge towards the surface. Furthermore, two pre-invasive (or
precursor) lesions (pTis) of signet ring cell carcinoma (SRCC) have been recognized exclusively in
CDH1 carriers, so far: (1) in situ SRCC, corresponding to the presence of SRC with hyperchromatic
and depolarized nuclei within the basal membrane of a gland replacing the normal cells of the gland;
(2) pagetoid spread of a row of SRC below the preserved epithelium of glands and foveolae, and also
within the basal membrane [18,19].
Endoscopic biopsies specimens from CDH1 carriers might also disclose features of poorly cohesive
(diffuse) GC with an “aggressive” phenotype, represented by pleomorphic, bizarre, and diffusely
infiltrative cells. These features are highly suggestive of advanced disease. Their presence, along with
the coexistence of typical SRC, should be described in the pathology report, to prompt staging and
clinical intervention [20].
Criteria for the identification of SRC lesions should be strictly followed in order to diminish the
risk of over-diagnosing of mimickers of SRCC or precursor lesions. In the gastrointestinal tract, various
benign “signet cell like changes” might mimic SRCC [21,22]. Therefore, confirmation of focal SRC
lesions in the stomach by a histopathologist with experience in this area is strongly recommended.
2.3. Histopathology of Prophylactic Gastrectomy
Macroscopic examination and sampling of prophylactic gastrectomies (PTG) should follow specific
protocols, and the histological examination should be made using a checklist [6].
Pathology data from over 170 total PTG in the setting of HDGC has been published until now [23].
Gross examination revealed HDGC lesions in only a minority of cases (11.7%), encompassing pale
patches, nodules, and tiny ulcers/scars. The majority of total gastrectomies from CDH1 carriers exhibit
tiny mucosal foci of SRCC or in situ SRCC, although sometimes these were only discovered after
careful review by an expert pathologist [18,24–33].
A recent review [23] demonstrated that when a thorough histopathological examination of the
entire gastric mucosa was not performed, HDGC lesions were found in only 62.5% of the total
gastrectomies. In contrast, when the whole gastric mucosa was examined according to total-embedding
protocol, precursor lesions or invasive carcinoma foci were identified in almost all gastrectomy
specimens (95.3%). Moreover, the application of total-embedding protocol considerably increased the
number of HDGC lesions identified. These findings argue in favor of the use of the total-embedding
protocol and the thorough histopathological examination of the entire gastric mucosa, as the gold
standard practice for the evaluation of total gastrectomy specimens from CDH1 carriers. However,
in laboratories under resource constraint, it might be impossible to perform total embedding of the
stomach. In these cases, the pathologists should clearly state, in the histological report, the percentage
of gastric mucosa that was examined.
According to the data published in the current literature, the number of pT1a carcinoma foci
found in total gastrectomy specimens from CDH1 carriers, ranged from 1 to 487 and the size varied
from <0.1 mm to 16 mm. The number of cancer foci is significantly higher in specimens with previous
positive endoscopic biopsies [23]. No correlation between the number, diameter, or location of the
HDGC lesions and the age, gender, or CDH1 germline variant of the CDH1 carriers has been described
so far. The detection of in situ carcinoma lesions is not as frequent as the detection of pT1a carcinoma
foci, suggesting that invasion of the lamina propria by SRC might occur without a morphologically
detectable pre-invasive lesion [18,34]. To date, discordant results are published regarding the anatomical
location of the cancer foci. Several authors reported a proximal clustering [25,30,31,35] while others
described the cancer foci, as dispersed throughout the stomach mucosa [18,20,29]. These findings are
in contrast with early reports in New Zealand Maori kindred, where most foci were found within the
body-antral transitional zone and in the distal stomach [26,27]. The cause of this variation remains to
be clarified. It is essential that the locations of biopsies within gastrectomy specimens are specifically
reported, to learn more about the distribution of early HDGC in the stomach.
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Finding invasive carcinoma beyond the lamina propria in total gastrectomy specimens from
asymptomatic CDH1 carriers is rare [31,33,36–38]. Lymph node metastases have been described in one
case with invasion of the subserosa (pT3) [36].
Surgical margin status must confirm that there is no residual gastric mucosa and tumor at the
margins. However, esophageal cardiac-type glands are scattered in the lamina propria through all
levels of the esophagus. The risk to develop SRCC in these glands is unknown but has not been
reported [39]. Metaplastic and heterotopic gastric mucosa can be seen elsewhere in the gastrointestinal
tract, and a mucosal SRCC was described in the duodenum [40].
Background changes in the gastric mucosa of PTG specimens encompass mild chronic gastritis,
which is a frequent finding (49%), sometimes displaying the features of lymphocytic gastritis. Foveolar
hyperplasia and tufting of surface epithelium, focally with globoid change, is also a frequent finding
and, in some areas, vacuolization of surface epithelium is very striking, however this does not seem to
be a specific finding. Intestinal metaplasia and Helicobacter pylori infection were found in 22% and
23% of total gastrectomy specimens, respectively [23].
2.4. Histopathology: Advanced HDGC
Advanced HDGC predominantly presents as linitis plastica with diffuse infiltration of the gastric
wall. Histology can show predominantly or exclusively SRC (“signet ring cell type” poorly cohesive
carcinoma). However, more often these tumors are composed of a pleomorphic neoplastic infiltrate
with a small subset of SRC (“non-signet ring cell type” or “not otherwise specified” poorly cohesive
carcinoma). In a minority of cases, tumor cells are arranged in small aggregates, sometimes rosettes
or glandular-like structures. A component of extracellular mucin might also be present, in which
the neoplastic cells float. Although morphological features are not specific, in situ lesions, including
pagetoid spread of SRC, in the surrounding non-neoplastic mucosa are important clues for the
hereditary nature of the tumor.
2.5. Histochemical and Immunohistochemical Stains
The use of histochemical stains for neutral mucins, such as PAS-D is useful for the detection
or confirmation of tiny intramucosal carcinomas in which the neoplastic cells are dispersed among
preserved foveolae and glands. This should be performed routinely in the examination of gastric
biopsies taken during endoscopy and in total gastrectomies from HDGC patients [41]. A cytokeratin
stain can help to confirm the epithelial nature of the SRC, if there is any doubt, as well as to confirm the
depth of penetration within the gastric wall.
Aberrant immunoreactivity of E-cadherin has been described in precursor lesions, as well as in early
and advanced carcinomas. In pagetoid spread of SRC and in situ SRCC, E-cadherin immunoexpression
can also be reduced or absent [18] (Figure 2). Heterogenous E-cadherin staining patterns have been
described in invasive lesions from CDH1 carriers, including complete loss of expression, reduced
membranous immunoreactivity, and “dotted” or cytoplasmic staining [42], however, the pathologist
should be aware that E-cadherin expression, as detected by immunohistochemistry, is not always
reduced or absent, and can be maintained independent of the presence of CDH1 mutation. Therefore,
E-cadherin staining should not be used as a pre-screening method to select patients eligible for germline
CDH1 alteration analysis.
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cadherin expression (IHC) shows absence or marked decrease of E-cadherin at the cell membrane of 
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diagnosis of early DGC is that tumor cells begin infiltrating the mucosa, while preserving a normal 
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focus is very often less than 1 mm in greatest diameter [29]. 
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Figure 2. Intramucosal HDGC, pT1a. (A) Signet ring cells are larger at the surface, foveolar type;
in the deeper zone, at the level of the isthmus, the neoplastic cells are much smaller, immature type.
(B) E-cadherin expression (IHC) shows absence or marked decrease of E-cadherin at the cell embrane
of signet ring cells.
Several studies compared the immunohistochemical profile of HDGC with the progression of the
disease. According to recent studies, the aberrant expression of p53, increased proliferation activity
(evaluated by Ki-67) [42], and over-expression of p16 [43] are emerging biomarkers of progression from
indolent to widely invasive HDGC lesions and adverse prognosis.
E-cadherin-null cells have numerous adaptations that affect the cortical actin cytoskeleton.
These changes appear to undermine the efficiency of the plasma membrane deformation processes,
establishing numerous druggable vulnerabilities [44], yet to be explored for the chemoprevention of
DGC and LBC [45].
2.6. Endoscopy
For patients with a pathogenic germline CDH1 variant, endoscopic surveillance is the only
alternative to PTG (if patient refuses). However, endoscopic detection of SRCC in CDH1 carriers is
poor, and histological evaluation of surgical specimens demonstrates cancer foci in up to 45–60% of
cases with a negative endoscopic evaluation [46,47]. The main factor that hinders the endoscopic
diagnosis of early DGC is that tumor cells begin infiltrating the mucosa, while preserving a normal
surface epithelium. Moreover, SRCC foci can be sparse (less than 2% of the gastric mucosa) and each
focus is very often less than 1 mm in greatest diameter [29].
For this reason, gastrectomy is advised, regardless of the endoscopic findings [6]. For individuals
who refuse surgery, despite carrying a pathogenic variant, a variant of uncertain significance (VUS),
or fulfilling the HDGC criteria without having a germline CDH1 mutation, annual surveillance starting
at age 20, following the Cambridge protocol, in experienced centers, is recommended [38].
According to the IGCLC endoscopy surveillance protocol, a careful examination in a dedicated
session of at least 30 min with high definition white light is recommended. Extensive washing of the
mucosa with the assistance of mucolytic and anti-foaming agents is advised, in order to allow for
careful evaluation of the entire gastric mucosa. Since the lack of distensibility is a sign of an infiltrative
process such as linitis plastica, repeated insufflation and deflation to maximize visualization of the
entire gastric mucosa, and a check for distensibility is suggested.
Prior to obtaining random gastric biopsies, targeted biopsies of all suspicious lesions, in particular
pale areas (considered more likely to have abnormal SRC), erythema, erosion, or other gastric
abnormalities should be taken. After sampling of all visible lesions, five random biopsies should then
be taken from each of the 6 anatomic regions—prepyloric, antrum, transitional zone, body, fundus, and
cardia, with these groups of biopsies each being sent separately for pathological analysis [6]. Given the
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large number of biopsies performed, it is recommended to stop anticoagulation, if possible, prior to
the procedure.
A model developed by Fujita et al. estimated that for a 90% detection rate, the theoretical number
of biopsies necessary is 1768 per patient, but this is not clinically feasible [31]. The main disadvantage
of taking an extensive number of biopsies is the formation of scar tissue, which can then mimic the
superficial pale aspect of SRCC lesions. Mi et al. showed that targeted biopsies (of typical pale lesions)
can result in detection of SRCC foci in more than 40% of patients, this approach has a sensitivity of
28% [48]. However, we have to consider other studies demonstrating that the pale areas are very
non-specific for SRC [35,38,49,50]. Further development of endoscopic techniques, such as electronic
enhanced imaging techniques, confocal endomicroscopy, magnification and artificial intelligence, is
warranted to improve the detection rate of SRCC foci. This procedure is indicated for microscopic
visualization of the mucosa during endoscopy at an approximately 1000-fold magnification, and might
limit the sampling error of untargeted biopsies [51].
2.7. Prophylactic Gastrectomy
The latest IGCLC guidelines recommend PTG, regardless of endoscopic findings, in early
adulthood (20–30 years) [6]. New guidelines are expected to be published very soon. PTG remains the
recommended option for GC risk management in pathogenic CDH1 variant carriers. However, there is
increasing confidence that endoscopic surveillance in expert centers can be safely offered to patients
who wish to postpone surgery or to those whose risk is not well-defined.
Family phenotype, especially the proband’s age at diagnosis, should be also taken into account.
Statistical models considering quality-adjusted life-years (QALYs) and cancer mortality have been
developed. The QALYs is a generic measure of disease burden, including both the quality and the
quantity of life lived. PTG in men at 39 years of age results in 32 incremental QALYs, and a lifetime
cancer mortality of 8.5%. Whereas for women, the optimal age for PTG is 30 years, with 33 incremental
QALYs, and a lifetime cancer mortality of 1.6% [52]. This model is hypothetic.
However, because PTG has a great impact on the quality of life with both physical and psychological
downsides, many factors need to be taken into account. First, the cumulative incidence of GC in
unselected CDH1 pathogenic variant carrier families, is significantly lower than in families pre-selected
for the HDGC criteria [9]. Second, age at diagnosis in the former group is higher and a substantial
proportion of families only present with BC [53]. As a consequence, clinical criteria for CDH1 testing
should be extended to families with BC cases only and delayed PTG should be considered in selected
cases. Another group of particular interest are individuals with a CDH1 pathogenic mutation, without
a family history of GC. The clinical management of these patients remain a matter of debate [54].
PTG can be performed either laparoscopically or open, based on the experience of the surgeon.
Intraoperative frozen section of the resection margins is recommended to ensure that no gastric
mucosa has been left behind [40]. Additionally a D1+ lymph node dissection is usually recommended.
Regarding the reconstruction technique—a jejunal pouch reconstruction has been suggested by some
surgeons [55] but there are no clear data indicating advantages of this more complex technique over a
standard direct Roux-en-Y, which is generally preferred.
The most significant side effect of a PTG results from a potential leak at the esophago–jejunal
anastomosis. Pooled data coming from 14 controlled randomized trials of gastric reconstruction,
after total gastrectomy demonstrated a mortality rate ranging from 0 to 22% [56], even though the
majority of current investigations from high-volume centers report mortality figures less than 3%.
The procedure is also associated with several side effects, such as early and late dumping syndrome,
malabsorption, and postprandial fullness. This procedure in fact is associated with the decrease of
vitamin B12 and protein absorption, bacterial overgrowth due to loss of parietal and chief cells of
the stomach, reflux, dumping, and weight loss. This nadirs after 3–6 months and averages at about
20% of pre-operative weight [57]. Postoperative follow up with experienced dieticians is crucial since
postoperative weight loss happens in all patients.
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3. Hereditary Lobular Breast Cancer (HLBC)
In Figure 3, we purposed a flow-chart for the clinical management of the HLBC syndrome.Cancers 2020, 12, x 8 of 25 
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3.1. Definition
The identification of CDH1 germline mutations in cases of LBC not associated with the classical
HDGC syndrome has led to the formation of a working group aimed at better characterizing the
genetic susceptibility, the pathophysiology and clinical criteria for this new syndrome, so called HLBC.
The working group agreed that the latest clinical criteria for the CDH1 genetic testing proposed by
the IGCLC are insufficient to identify patients at risk of HLBC. Therefore, novel criteria have been
proposed—(A) bilateral LBC with or without family history of LBC, with age at onset < 50 years; and (B)
unilateral LBC with family history of LBC, with age at onset < 45 years. Following the above-mentioned
clinical criteria, a CDH1 germline mutation could be identified in 3% of the screened population [7].
3.2. CDH1 Screening: Preliminary Considerations
The ongoing trial “Understanding how CDH1 germline mutations affect HLBC” [58] is a clinical
genetic study that aims to identify the role of CDH1 in HLBC without DGC aggregation. The first
aim of this study is to investigate the prevalence of CDH1 mutations in women with early onset (<45
or <50) invasive or in situ LBC, bilateral LBC, and LBC with no family history of HDGC. To date,
120 patients were enrolled and 6 CDH1 germline variants were identified—1 splice site variant of
unknown significance (VUS) and 5 missense (3 VUS and 2 pathogenic) variants. CDH1 germline VUS
are under evaluation at the IPATIMUP laboratory in Porto, Portugal to assess their pathogenicity.
3.3. Pathology
No specific diagnostic features have been observed in HLBC, compared to non-HLBC. However,
appropriate pathological management is crucial to improve patients’ outcome, both in the screening
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and surgical setting [59]. Akin to LBC, these syndromic tumors are morphologically characterized
by the presence of non-cohesive small, uniform, round neoplastic cells that are loosely dispersed
throughout a variably dense fibrous stroma or arranged in a linear growth pattern [60]. Most commonly,
these tumors are of low or intermediate histological grade (Nottingham grade 1/2) and display a
complete or partial loss of E-Cadherin expression [7]. A variable spectrum of non-invasive lobular
neoplastic lesions, such as atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS),
are often observed in association with LBC [61]. These non-obligate precursors of invasive BC are also
characteristically E-cadherin negative, confirming that alterations in CDH1 are very early oncogenic
events in these patients [62]. Given that atypical lobular hyperplasia (AL) and lobular carcinoma in situ
(LCIS) are considered risk indicators for subsequent development of BC, we recommend an extensive
sampling of the surgical specimen in CDH1 mutations carriers. Likewise, the observation of these
non-invasive lobular lesions in bioptic samples in the presence of a possible hereditary gastric and BC
syndromes, warrants a multidisciplinary discussion for clinical decision-making [63]. In patients with
a history of DGC or LBC, or with documented CDH1 germline mutations, the tumor origin differential
diagnosis is not trivial in metastatic settings. Hence, the morphological similarities between these
two tumor types can be misleading in the metastatic site. In this setting, despite being nonspecific,
cytokeratins 7 and 20 can be helpful, together with GATA Binding Protein 3 (GATA3) and the homeobox
protein CDX2 (Table 1). It should be noted, however, that the observation of a metastatic poorly
cohesive adenocarcinoma from an unknown primary site remains a clinical problem that requires a
multidisciplinary diagnostic management.
Table 1. Panel of expressed markers in diffuse gastric cancer (DGC) and/or lobular breast cancer (LBC).
Markers DGC LBC
Cytokeratin 7 +/- +
Cytocheratin 20 -/+ -
GATA3 - +
CDX2 +/- -
3.4. Breast Imaging
Due to its non-cohesive histological growth pattern, often without a significant desmoplastic
reaction, the detection of invasive LBC on mammography is notoriously difficult [64]. The sensitivity
of mammography for the detection of all types of invasive breast carcinomas, ranges from 63% to
98% [65,66]. Due in part to the histopathological features of LBC described above, the sensitivity of
mammography in detecting LBC is lower, ranging between 57% and 81% [67–69]. The most common
mammographic sign of LBC is an irregular, speculated mass, followed by architectural distortion and
asymmetries, while microcalcifications are uncommon. The mammographic diagnosis of LBC is also
limited by the fact that the density of LBC, on mammography, is similar to, or less than that of the
normal surrounding glandular tissue—due to the non-cohesive nature of the LBC cells—challenging
the mammographic detection. Recognizing that mammography has a limited value in the detection of
LBC, US plays an important role in the evaluation of suspicious physical exam findings. The overall
sensitivity of US for the detection of ILC is reported to be between 68% and 98%, and increases with
the use of higher frequency probes [70]. The most common ultrasound manifestation of LBC is an
irregular mass, with hypoechoic and heterogeneous internal echoes, ill-defined or speculated margins,
and posterior acoustic shadowing, findings that are seen in 54–61% of cases [71,72]. Breast magnetic
resonance imaging (MRI) has an overall sensitivity of 93% for detecting LBC, similar to the detection of
BC overall (90%) [73]. In case of non-indication for prophylactic mastectomy (Figure 3), accurate breast
imaging follow-up in CDH1 carriers is recommended. Data regarding the best time interval and best
modality is lacking and to date, no international guidelines exist. We recommend the use of annual
breast MRI followed by mammography and ultrasound at six months interval, similar to the schedule
followed for BRCA1/2 carriers.
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3.5. Surgical Management
When considering surgical management for CDH1 carriers, several considerations must be made.
First of all, it is important to distinguish between carriers who are already affected versus those
who have not developed BC yet. According to the recent ASCO 2020 guidelines, neither BRCA nor
moderate-penetrance gene mutations should preclude breast-conserving therapy (BCT), when this
is clinically appropriate [74]. At present, due to lack of data on contralateral BC risk, risk-reducing
surgery in affected CDH1 mutation carriers is not recommended [7]. Similarly, data for recommending
prophylactic surgery is lacking. However, mutation status is not the only factor to take into account
when considering local therapy decisions; family history, ability to undergo high-risk screening
procedures, and patient preference are important factors to evaluate and take into consideration [75].
In our opinion, information on risk-reducing surgery should be provided to carriers with a diagnosis of
LBC who have a clinical indication for mastectomy or already had a mastectomy as part of their cancer
treatment. Similarly, information on prophylactic surgery should be provided to individuals with a
positive family history for LBC and a well-documented CDH1 pathogenic alteration in a first-degree
relative [76].
The goal of prophylactic mastectomy is to achieve maximum risk reduction, by completely
removing the breast gland but at the same time achieving the best cosmetic result. These aims can be
reached through nipple-sparing mastectomy (NSM) with immediate reconstruction, which allows to
preserve the skin envelope as well as the nipple-areola complex (NAC). Patients should be informed
of the possible surgical and oncological risks of this procedure, which are the risk of local cancer
recurrence and the risk of skin necrosis. In terms of oncological safety, the presence of residual
breast tissue has raised concerns about this procedure [77]. However, multiple NSM series have
been published, and they almost all showed acceptable local recurrence rates [75,78,79]. NSM is also
associated with surgical morbidity [75,80], however, in a large series of nearly 2000 consecutive cases
from our institution, the rate of nipple necrosis in invasive and in situ cancers was 3.5% and 2.2%,
respectively [81], confirming the surgical safety of this technique. Several studies have evaluated the
impact of NSM on quality of life [82,83]. A recent systematic review of 22 studies on patient reported
outcomes after NSM, 70% of patients were satisfied with their choice, 65% maintained a positive body
image, and 95% had no regrets [84].
NSM is technically challenging, as the surgeon must completely and precisely remove the
mammary gland by preserving the skin envelope with its sub-dermal vascularization, the nipple,
and the inframammary folds [85]. The upper outer linear skin incision is the most commonly used,
but surgical approach can be personalized in relation to several clinical peculiarities—indeed, different
skin incisions for NSM have been proposed in the literature (hemi-periareolar, round block, vertical
pattern, and wise pattern skin incisions) [86].
Robotic NSM is currently being tested in clinical trials. A recent study confirmed technical
accuracy, feasibility, satisfaction, and high tolerance rate of patients. The advantage of this technique,
compared to the conventional standard NSM, consists mainly in a smaller extra-mammary skin access
with the same technical effectiveness [87]. An ongoing randomized clinical trial comparing open NSM
and robotic NSM in the prophylactic setting will provide further data on the long-term oncological
outcome of this technique [88].
3.6. Post-Mastectomy Breast Reconstruction
Breast reconstruction is tailored to each patient, taking into consideration patient anatomy and
comorbidities, cancer staging and oncological rules if present, and even patient desires. It requires
a close collaboration between a general and plastic surgeon, if a double team approach is used.
However, the rates of reconstruction are largely varying, according to different countries and single
institutions [89,90], and among women themselves [91,92].
In case of healthy breasts, a conservative mastectomy is usually performed with “aesthetic”
surgical incisions. Nipple and areola complex can be preserved. Surgical incisions might be hidden in
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natural folds of the healthy breast (i.e., inframammary fold, axillary) or just around the areola, resulting
in very natural breasts.
With regard to mastectomies for cancer treatment, tumor location and staging certainly influence
the surgical approach and skin incisions. For those tumors superficially located, the skin over the
tumor is removed within the mastectomy specimen, influencing the resulting scar.
Regardless of the type of mastectomy, options for reconstructions include both prostheses and
autologous tissues [90].
Definitive silicone implants or temporary prostheses are conventionally placed below the pectoralis
major muscle. More recently, prepectoral reconstructions allow more natural results and lower
morbidity [93–95]. On the contrary, other patients prefer using autologous tissues, if applicable,
because of the similarity to natural breast, stability of the long-term result and anxiety about using
foreign materials. Autologous reconstruction encompasses a broad range of procedures incorporating
the patient’s own tissues to recreate the breast mound (pedicled and free flaps, fat grafting).
In case of bilateral risk-reducing surgery, the bilateral reconstructions with implants might be
really satisfactory, especially in case of small to medium breasts when nipple and areola are preserved,
or if reducing patterns in large breasts are successfully used.
Finally, even more challenging are post mastectomy reconstructions after previous conservative
surgery and irradiation. It occurs in those patients with hereditary gastric and breast cancer
syndromes who have been treated for primary cancer with conservation and who require risk-reducing
mastectomies after genetic testing. In fact, mastectomy and reconstruction in irradiated breasts leads
to higher postoperative complications, due to impaired flap vascularity and healing process after
radiotherapy, the presence of previous scars, and increased capsular contracture in case of implant use.
In irradiated breasts, autologous reconstructions are the methods of choice, or more recently, the use of
biological matrices and implants has been advocated to decrease capsular contracture rate.
4. Common Managements
4.1. Genetic Counseling
A multidisciplinary approach can ensure optimal management of the CDH1 germline mutation
carriers. Genetic counseling by clinical geneticists with expertise in the field is a critical component
of the risk assessment. To identify individuals with HDGC, the clinical evaluation should include
collection and review of personal and family history with detailed three-generation family pedigree
and confirmation of DGC or LBC diagnoses. The latest IGCLC consensus guidelines [6] suggest CDH1
germline testing in a proband with one or more of the following features—(a) personal history of
GC with one or more relatives with GC, regardless of age, in which there is at least one confirmed
DGC; (b) personal history of DGC before 40 years; (c) personal or family history of DGC and LBC, one
diagnosed before 50 years; (d) personal history of bilateral LBC or family history of two or more cases
of LBC diagnoses before 50 years; (e) personal history of DGC and personal or family history of cleft/lip
palate; (f) in situ SRC or pagetoid spread of SRC. Criteria will be updated in the new IGCLC guidelines.
Family history should be considered positive in presence of one or more first- or second-degree
relatives. It is to note that the suspicion of HDGC could be underestimated in individuals with
unknown or limited family history. Initial testing should be considered in an affected proband and
when more than one family member is affected with cancer, consider starting from individual with a
confirmed diagnosis of DGC or with youngest age at diagnosis. Unaffected individuals should be
tested only when affected family member is not available and informed of possible limitations in
interpreting test results. An individual (healthy or affected) with a known familial pathogenic (or
likely pathogenic) variant could be offered gene testing for the specific familial variant.
Genetic testing in individuals younger than age 18 years could be considered in families with cases
of early-onset [96]. Of note, diagnosis of DGC before 20 years is rare [97]. Gene testing of individuals
younger than age 18 years requires counseling for both the parents and the child.
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Genetic testing can be performed on DNA extracted from blood or buccal samples, except for
patients who have received allogeneic bone marrow transplant or with a recent diagnosis of hematologic
malignancy (DNA from a fibroblast culture is a preferable sample in these patients).
CDH1 gene analysis should include search of point mutations and large rearrangements by Sanger
sequencing and multiplex ligation-dependent probe amplification (MLPA) or by next generation
sequencing (NGS). Point mutations (about 30–50% of all variants) might include small intragenic
deletions/insertions and missense, nonsense, and splice site variants [4,98]. Exon or whole-gene
deletions/duplications have been detected in 6.5% of individuals with HDGC and without pathogenic
variants on sequence analysis [99]. CDH1 germline variants are classified according to the IARC
5-tiered classification system in five classes (Class 5: Pathogenic, Class 4: Likely Pathogenic; Class 3:
Variant of Uncertain Significance or VUS; Class 2: Likely Benign; Class 1: Benign) [100]. The ACMG
variant classification guidelines published in 2015 [101] have recently been revised for the analysis of
germline CDH1 sequence variants [102].
During genetic counseling, the likelihood of a positive test, technical aspects, inheritance pattern,
and significance of the possible outcomes of testing, such as positive (i.e., pathogenic or likely
pathogenic variant), inconclusive or uncertain (i.e., VUS), or uninformative (i.e., no mutations detected),
or true-negative (i.e., absence of the known familial mutation) should be discussed. A discussion on
life-time risks of DGC or LBC, and PTG, or options of surveillance, should be provided. The counselee
should be informed about potential significance of the test results for the family, and about reproductive
options, such as the availability of genetic testing through prenatal and preimplantation genetic
diagnosis. Genetic counseling should include discussion on the need of a continuous update of VUS.
Testing a family member for a VUS should not be offered in clinical setting but could be considered
for research purposes. Patients and families suggestive of HDGC with uninformative results (about
50–70% of cases), might have an undetectable defect in CDH1 gene (i.e., mosaicism, sequence variant
in an intron or regulatory region, or others not covered for technical limits) or pathogenic variants in
other cancer predisposition genes. Therefore, intensive endoscopic surveillance is recommendable
for first-degree relatives of patients meeting criteria for CDH1 germline testing with uninformative
results. Nowadays, genetic testing includes two main clinical approaches—single-gene testing or
MGPT [103–105]. The spread of MGPT has led to the identification of CDH1 germline pathogenic
and likely pathogenic variants in individuals without a personal and family history, suggestive of
HDGC. This kind of results poses major clinical management challenges [106]. Secondary findings
could be explained by the presence of families or CDH1 germline mutations with reduced penetrance,
and there is a strong need for specific studies in order to obtain more data and drive specific clinical
management guidelines.
4.2. Psychological Counseling
CDH1 carriers face several challenges, including the burden of cancer treatment, if already affected
by DGC or LBC, and the need to decide upon prophylactic surgery if still unaffected. As a result,
individuals might experience depressive symptoms [107,108], general distress [108–110], and anxiety
(109), which can impact their decision-making abilities [111–113]. Psychological support is, therefore,
a key component of the multidisciplinary management of these patients [114]. To help manage the
psychological and medical burden, improve coping skills and the decision-making process, counseling
should include a strong psycho-decisional support component [115,116]. The approach should
be personalized by taking into consideration the patient’s personality, age, lifestyle, psychological
well-being, social support, and self-efficacy [115,117–119]. The final aim is for patients to better
communicate with their healthcare providers, in order to determine the most adequate preventative,
and therapeutic options [120]. Psychological counselling and decision-making support are important
tools through which counsellors and health care providers can strengthen patient autonomy and provide
informed self-care aligned to the patient’s own deliberative decisions [121]. Empowered patients [122]
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express higher satisfaction towards the care received, higher trust in healthcare providers [123], better
adherence, and less conflict with healthcare providers [124].
This approach is very recent and should be addressed by HDGC and HLBC investigators in
the future.
4.3. CDH1 Missense Variants: Challenging Routine Laboratory Tests
The implementation of MGPT has led to a dramatic increase in the identification of missense
variants. Determining the clinical relevance of such variants is currently a major goal in genomic
medicine [125–127].
In HDGC, CDH1 missense mutations occur in 22% of cases [128,129] and a large proportion of
variants remain unclassified [102]. We, therefore, recommend that a complementary set of analyses
encompassing familial and population data, as well as in silico and in vitro tests should be carried
out to determine putative variant pathogenicity [130,131]. The assessment of variant effects cannot be
achieved by standalone evidence in a single category nor by population, in silico or in vitro tests, since
all approaches have limitations [101].
Genetic parameters such as mutation frequency in healthy control population, co-segregation of
mutation with the disease within pedigrees, and mutation recurrence in unrelated families should be
considered as a first approach [128,129]. Variant frequency in different ethnic groups can be assessed
through genomic databases, which compile data from large sequencing consortiums with a few to
several thousand participants, namely the 1000 Genomes Project (http://browser.1000genomes.org),
the Trans-Omics for Precision Medicine Program (TOPMed; https://www.nhlbiwgs.org/), or The Genome
Aggregation Database (gnomAD; https://gnomad.broadinstitute.org/). Nevertheless, databases have
limitations, including low-quality data, lack of details on the origin of studies or absence of information
regarding possible associated phenotypes [101]. Moreover, the segregation of a variant within
a population at low (<1%) or very low (<0.1%) frequencies per se cannot exclude pathogenicity,
especially in the presence of clinical and experimental evidence supportive of variant deleterious
effects. As HDGC caused by missense mutations has low penetrance [128,132], other host genetic and
environmental factors are expected to play a role in the presentation of clinical phenotypes and disease
onset. A comprehensive analysis of the pedigree is, thus, crucial to evaluate variant significance and
disease risk in germline carriers. Nevertheless, this can be challenging, given the small size of the
families and lack of information from patient relatives [128,129].
In silico predictions are valuable tools to estimate the degree of conservation of mutated aminoacids
within species, their impact on splicing and, ultimately, on the protein structure [128]. However, the use
of multiple programs is mandatory, as different outputs can be obtained, depending on the underlying
algorithm [101]. Predictions are based on the principle that aminoacids conserved across species are
functionally relevant and their substitution is likely to affect protein function [128,133]. The limitation of
this approach is that the degree of conservation of each aminoacid is considered separately and, as such,
possible compensatory effects of neighboring positions are not contemplated [128]. Structural modeling
is currently suitable to predict the impact of most missense mutations in E-cadherin native-state
stability, by covering the major part of protein, including the prodomain, the extracellular, and the
catenin-binding domains. A correlation between variants that induce higher energetic penalties and
their in vitro loss of function has been clearly demonstrated [133].
In the last few years, a panel of in vitro assays has been developed specifically to assess CDH1
sequence variants [131,134–137]. The workflow starts by transfecting cell lines with vectors encoding
the variant and the wild-type protein. Subsequently, protein expression level, protein localization,
and main E-cadherin functions (cell-cell adhesion and invasion suppression) are evaluated [131,134,135].
The CHO (Chinese Hamster Ovary) cell line is the conventionally accepted model to perform all
tests, as this cell line is completely negative for cadherin protein expression and displays in vitro
invasive properties. Upon transfection with the wild-type E-cadherin, CHO cells acquire the capacity
to form cellular aggregates on soft agar and become non-invasive through artificial extracellular
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matrices [130,134,135]. The effect of missense variants on E-cadherin expression level is assessed by
western blot. Low E-cadherin expression strongly indicates structural destabilization and premature
degradation of the protein through mechanisms of Protein Quality Control [133]. Immunostaining and
its detailed quantitative analysis is then used to address whether the variant induces abnormal patterns
of E-cadherin localization [136]. Occasionally, a band mobility shift can also be observed, suggesting
aberrant glycosylation of the protein [138,139]. Contrary to wild-type E-cadherin, which is normally
present at the plasma membrane, deleterious variants can be diffusely distributed throughout the cell or
abnormally accumulated in cytoplasmic regions/organelles [135,136,140]. Remarkably, some deleterious
variants are expressed at the plasma membrane, affecting the stability of the interaction between
cadherin molecules (on adjacent cells) and increasing protein turnover rates [135,136,141]. Cell–cell
adhesive abilities of variants are evaluated by slow aggregation assays. In this technique, a single-cell
suspension is seeded on a semi-solid agar substrate and cells with a competent adhesion complex
spontaneously aggregate [142]. It is well-established that cells transfected with the wild-type protein
form compact cellular aggregates, while cells with dysfunctional E-cadherin form small cellular
aggregates or present an isolated phenotype [134,135,143]. Topological features in cell meshes should
also be examined to determine morphological and structural consequences upon adhesion loss. Indeed,
it was demonstrated that triangles within cell networks of dysfunctional mutants have bigger areas
and edges, when compared with those formed by wild-type cells, which indicates that E-cadherin
defective cells are loosely attached and display increased protrusion formation [137].
The invasive suppressive potential and interaction of E-cadherin mutant cells with the surrounding
extracellular matrix (ECM) are currently being studied using matrigel invasion chambers. Matrigel is
the most frequently used ECM in invasion assays and its major advantage lies on its heterogeneous
composition [144]. This matrix contains not only structural proteins, such as collagens, fibronectin,
laminin, and proteoglycans, but also a panel of growth factors, mimicking the basement membrane
composition in vitro [144,145].
A major limitation of in vitro experiments is the time pressure surrounding genetic counseling.
Nonetheless, and despite the fact that these assays are low throughput and technically challenging,
their results reflect a broad approach evaluating alterations in protein structure, trafficking, cellular
signaling, and function, which would be impossible to predict through in silico analysis [130].
By following this analytical pipeline, it is possible to determine the functional impact of 85% of
E-cadherin missense variants. However, in 15% of cases, these assays are not sufficient to assure a
confident result, and their functional significance remains inconclusive. In such cases, other approaches
including cell migration analysis, assessment of the interplay between E-cadherin and its binding
partners (by proximity ligation assays), as well as evaluation of downstream targets activation can be
applied [135,141,146,147]. In vivo models are also being developed to study variants that still lack a
clear functional classification.
Overall, a comprehensive approach aggregating multiple lines of evidence will be crucial to
correlate variable effects of missense alterations with disease penetrance and phenotypes. Moreover,
given the pleiotropic nature of CDH1 variants, a careful interpretation of data should take into account
the disease context, including diffuse GC, LBC, or congenital malformations, so a proper management
can be offered to CDH1 variant carriers.
4.4. Bioimaging Strategies to Identify Aberrant E-Cadherin Expression Signatures
For most cancer types, to support the diagnosis and orientation of therapeutic strategies,
the analysis of specific proteins is often required, as alteration in expression or localization of
proteins is commonly observed. Immunofluorescence is currently performed to identify aberrant
patterns of E-cadherin expression, indicative of protein deregulation and functional impairment at
the cellular level, while maintaining tissue architecture [131,135,138,148]. In parallel with a proper
staining method, the adequate acquisition and quantification of E-cadherin expression is mandatory.
Several high-resolution microscope imaging modalities, such as time-lapse, confocal laser scanning
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microscopy (CLSM) and spinning disk microscopy can be used in the acquisition of immunofluorescence
images for subsequent examination. However, image analysis is mostly qualitative and strongly
operator-dependent [149–151], which is likely to influence the biological and clinical evaluation of the
data. Quantitative approaches are, thus, essential and required to be implemented for an accurate
data interpretation.
Over the last decade, a number of software systems has emerged that aims at the quantification of
specific features in microscopy images. Nevertheless, these tools often measure total fluorochrome
intensity in defined areas, neglecting the expression profile of the target protein in distinct
subcellular/cellular/tissue compartments and possibly failing to recognize events of protein
delocalization [152,153]. Additional limitations include the discrepancy of parameters during image
acquisition and quantification among different experiments and the lack of tools to take into account
cell heterogeneity, with respect to morphology (size and shape). Therefore, in order to overcome
the current limitations and in view of the urgent need to implement automatic quantitative tools,
a novel bioimaging strategy was recently developed [136,154]. This new pipeline allows for a detailed
characterization of protein expression with regard of its level and distribution in intra and intercellular
spaces. More specifically, the developed algorithm is able to map specific protein signatures, in images
of single cells or cell populations, in a multistep process encompassing automatic selection of cells,
networking of cells upon nuclei segmentation and recognition of their geometric centroids [136,154].
Fluorescence signals detected between the centroids of two contiguous cells (internuclear profiles)
or in radial profiles from a single cell/centroid are then evaluated. Notably, internuclear profiles are
of particular relevance to the study proteins located at the plasma membrane or in specific cellular
organelles. In contrast, radial profiles should be employed to capture signals throughout the cytoplasm
of single cells and are very useful to investigate cytoplasmic proteins. Overall, and as expected,
the compilation of all profiles generates a complex and highly heterogeneous protein map, due to
the morphological variability of the cells. Therefore, to solve this drawback, geometric compensation
techniques are applied, allowing the extraction of a representative profile of protein distribution in
the whole cell population [154]. Geometric compensation is indeed a common procedure used in
several image modalities and consists of the estimation of rigid or non-rigid transformations to bring
the objects under alignment, as similar as possible in terms of shape and size [155–158]. Ultimately,
a comprehensive dataset of fluorescence intensities and their respective locations is generated. With
this innovative approach, a new window of intervention has emerged, not only to identify protein
patterns associated with cancer but also to help disclose their related molecular mechanisms.
The value of this pipeline was demonstrated in different studies addressing the functional impact
of E-cadherin variants [136,159]. Immunofluorescence images of cells transfected with wild-type
E-cadherin and with a panel of cancer-related variants were subjected to the described bioimaging
processing. As verified by Sanches and collaborators, cells expressing E-cadherin dysfunctional
variants present a distinct profile from that displayed by the wild-type cells [136]. More specifically,
the variants induce a significant decrease in fluorescence intensity at the plasma membrane or aberrant
intensity peaks in the cytoplasm. Remarkable differences were also detected between the typical
virtual cells produced by the wild-type and variant expressing cells, suggesting abnormal E-cadherin
trafficking and protein accumulation in distinct cell compartments [136,159]. Based on these results,
bioimaging approaches have been proposed as a complementary method to assess the functional
relevance of novel E-cadherin missense variants, found in the context of HDGC [6,132]. Interestingly,
the same algorithm proved to be efficient in the quantification and mapping of a panel of molecules,
including P- and E-cadherin, tubulin, and a mitochondria dye, which are distributed in distinct cellular
compartments [154,160]. This could be of particular importance in diagnostic and research laboratories
to unravel protein regulation mechanisms or identify predictive biomarkers of the disease.
In the future, a combined approach of quantitative distribution of biomolecules with morphological
parameters such as cell area and cytoskeletal organization, would be of great value to determine
molecular pathways involved in disease progression, but also in the analysis of drug-screening
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strategies, pinpointing compounds that better rescue protein scores and, simultaneously, normal
cellular phenotypes. Modern machine-learning and data mining techniques could be explored to
develop more sensitive and efficient methods for signal detection and quantitative molecular analysis
in tissue samples.
5. Others
5.1. Clinical Management of CDH1 Carriers without a Family History of GC and LBC
The introduction of MGPT for hereditary cancer susceptibility has caused an increase in the number
of CDH1 mutations detected [161]. Although rare, such mutations have been discovered in subjects
who do not fulfill the clinical criteria established by the latest IGCLC meeting [6]. The cumulative risk
of GC and BC in this group of patients is unknown [92] and no management guidelines exist.
In our opinion, in the absence of a clear family history for DGC or LBC, asymptomatic CDH1
pathogenic mutant carrier, should be monitor closely. However, if after multidisciplinary discussion,
PTG is opted to be the best approach, the patient should be thoroughly informed of all side effects and
of the lack of long-term outcome data.
5.2. High and Low-Risk Geographical Regions for GC: Impact on Clinical Management
The worldwide incidence of gastric carcinoma varies greatly by region, so that some geographical
areas are considered high- and other as low-risk. The cause of this variability is multifactorial.
Interestingly, clinicopathological features of GC in these two areas are different. Lauren diffuse-mixed
histotype, younger age, advanced stage, and worse prognosis are more likely in low-risk GC area [162];
whereas clear environmental factors, such as diet, are more frequent in high-risk areas [163,164].
CDH1 mutation frequency (including missense mutations) is higher in low-risk area for GC compared
to high-risk areas [165] where GC seem to be “CDH1 independent”.
As a general rule, in high-risk areas, CDH1 negative individuals with a positive family history for
GC, should follow diet recommendations and have gastric endoscopic surveillance whereas in low-risk
area, these individuals might benefit from MGPT.
6. Conclusions
As the understanding of the pathogenesis of this complex syndrome continue to improve, there is
a clear need to constantly revise clinical criteria for CDH1 genetic screening. The identification of CDH1
germline mutations in individuals, who do not fulfill the classic IGCLC clinical criteria, raises new
questions on how to manage these patients. HDGC syndrome is likely a much more complex disease
than what was initially thought. In this review article, we discussed different aspects that should be
included in the clinical management of these patients. PTG remains the only life-saving approach
for individuals carrying deleterious germline mutations and fulfilling the HDGC criteria, however,
great caution is needed in the absence of family history for GC. Different clinical approaches should be
considered in different geographical regions. Prophylactic mastectomy should be discussed in CDH1
carriers with a strong aggregation for LBC, fulfilling the established clinical criteria. In asymptomatic
CDH1 carriers who do not fulfill the clinical criteria, surveillance is preferred. Risk reducing surgery
should be only considered in patients who need a mastectomy or had a mastectomy in the past.
Given the complexity and the rarity of this syndrome, CDH1 carriers should always be treated in
a multidisciplinary fashion and in high-specialized cancer centers.
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